|
Recruiting
|
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
|
|
Terminated
|
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 |
|
Completed
|
NCT00332969 -
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
|
Phase 2 |
|
Completed
|
NCT00921739 -
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
|
Phase 1 |
|
Recruiting
|
NCT05255965 -
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
|
|
|
Withdrawn
|
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
|
|
Completed
|
NCT00387868 -
Preoperative Treatment of Patients With High Risk Thymoma
|
Phase 2 |
|
Completed
|
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A |
|
Recruiting
|
NCT03466827 -
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
|
Phase 2 |
|
Completed
|
NCT02220855 -
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
|
Phase 2 |
|
Completed
|
NCT03288662 -
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
|
N/A |
|
Active, not recruiting
|
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 |
|
Recruiting
|
NCT06029621 -
Robot-assisted vs VATS for Thymoma
|
N/A |
|
Recruiting
|
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 |
|
Recruiting
|
NCT06248515 -
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
|
Phase 2 |
|
Active, not recruiting
|
NCT01621568 -
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
|
Phase 2 |
|
Recruiting
|
NCT05262582 -
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
|
N/A |
|
Terminated
|
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 |
|
Active, not recruiting
|
NCT03968315 -
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
|
N/A |
|
Recruiting
|
NCT06086327 -
Application of 68Ga-Pentixafor PET/CT for Thymoma
|
Early Phase 1 |